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Over the last two decades, a new therapeutic
paradigm has emerged which has changed the way
debilitating diseases may be treated in the future.
Instead of using small-molecule drugs and devices to
ameliorate the symptoms of disease, clinicians may
harness the therapeutic power of cells to regenerate
and cure diseases which currently represent a major
unmet medical need. Advancements in the scientific
knowledge of stem cell biology, along with highly
encouraging preclinical proof-of-concept studies, in
the last several years have served as a launch pad
for testing such therapeutics in humans with
life-threatening diseases. However, translating basic
research findings into human therapy has not been
straightforward and has presented many scientific,
clinical, and regulatory challenges for scientists and
clinicians. In this article, we provide a guidance
framework for investigators for the design of
early-phase clinical studies using stem cell-based
therapeutics. Furthermore, important trial parameters
and design features which must be considered before
regulatory submission of such studies are highlighted.translating discoveries into practice, physicians and sci-
entists must understand how regulatory agencies assessIntroduction
Stem cell therapy has enormous potential to alleviate
human suffering and to provide solutions to conditions
with a current unmet medical need. The number of clin-
ical indications for use of these cells and the powerful
therapeutic properties have produced a groundswell of
interest by physicians around the world to translate sci-
entific discoveries into patient benefit. Used as drugs,
stem cells are required to follow the regulatory pathway* Correspondence: timothy.obrien@nuigalway.ie
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used as drugs in investigator-initiated protocols, and so
investigators need to be aware of these regulatory path-
ways from the earliest stage of the translational process.
Furthermore, the nature of cells as drugs is more complex,
and the translational pathway to development will require
special considerations. The purposes of this review are
to serve as a primer for physicians who want their
laboratory-based discoveries in stem cell therapy to be
translated to clinical trials, to encourage investigators to
consider the required regulatory steps from the earliest
stage of the translational process, and to improve the
efficiency of translation of these important discoveries.Regulatory agencies as gatekeepers to
translational science
No stem cell trial can proceed without review and ap-
proval by regulatory authorities. Regulatory agencies and
investigators share a similar goal: to bring safe and effi-
cacious novel therapies to patients. These authorities
provide critical, independent assessment of a protocol to
determine whether the protocol meets the requirements
to reduce risk to patients. To maximize the efficiency of
new applications. These agencies must assess the current
evidence of the potential for safely testing a novel ther-
apy to determine the risk regarding its use in humans.
Safe use in humans takes into consideration the drug (its
manufacture, purity, and potency), its route of adminis-
tration, and the potential adverse effects in the environ-
ment of the disease to be treated. The inherent paradox
in new drug development is the combination of the as-
sessment of drug safety in the context in which it has
never been used. This paradox is managed by measuring
the strength of the supporting data (preclinical data and
related human clinical trials) in relationship to the risk
of potential harm (known or unknown) to the patient. Itle is distributed under the terms of the Creative Commons Attribution 4.0
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risk to those patients with few therapeutic options and a
poor prognosis. Understanding and mitigating this risk
are the responsibilities of the investigator during the ap-
plication to regulatory agencies, and effectively address-
ing the risk through proper preclinical studies and
identification of appropriate patient populations can
catalyze approval of the protocol. For example, sequen-
tial patient enrollment whereby a cohort of patients are
put on trial and observed for adverse events prior to the
next patient cohort enrollment can reduce the overall
risk to patients in the protocol. Other risk mitigation
strategies include careful preclinical studies that carefully
mimic the clinical trial and careful inclusion criteria that
describe a patient population with as uniform a progno-
sis as possible.
General comments on when it is appropriate to
progress to first-in-human studies
There is controversy in the stem cell field concerning
the amount of basic science knowledge required before
clinical trials should occur [1]. Although it is true that
stem cell therapeutic mechanisms are unknown or hypo-
thetical, many drugs currently in use for decades also lack
detailed elucidation of the mechanism of action. Investiga-
tors should consider the current knowledge concerning
the mechanism of action, the alternative treatment op-
tions, the severity of the underlying illness, and (if known)
the safety profile of the investigative drug. Final criteria for
exposing patients to the risks of these new therapies
should be a balance between the knowledge (including
mechanism of action and safety profile) of the drug (or its
bio-equivalent), an evaluation of the potential alternative
therapies, and the ability of the investigator to adequately
monitor for drug-related adverse events.
Risk assessment based on clinical protocol
Key to appropriate risk management are the
characterization and understanding of the patient prog-
nosis. Protocols should be designed to identify a specific
patient population with as few co-morbidities as pos-
sible. A narrowly defined patient population must be
weighed against patient accrual, but generally the trial
should be performed in a well-defined population with a
predictable clinical course. Ultimately, the risk of any
drug is measured within the patient. Establishment of
drug safety in a patient cohort is the foundation of all fu-
ture trials of the drug. Understanding the pathology for
a specific patient population allows accurate attribution
of adverse events to the study drug. Allowance of a
broad spectrum of patients into safety trials can mark-
edly complicate this attribution. Complex patient popu-
lations therefore require more sophisticated preclinical
safety data to accompany the application as well aslarger trials and sophisticated measures of attribution.
As it is ethical for patients with extremely poor progno-
sis and no alternative acceptable therapies to assume
more potential risk in the evaluation of new drugs, a
balance must be struck during the identification of
the appropriate patient populations. A uniform patient
population with predictable prognosis and few alterna-
tive treatment options would be ideal. However, patients
with extremely advanced disease may not allow the time
to evaluate the safety of the drug in the form of drug-
mediated disease progression or may experience disease-
mediated co-morbidities that prevent gathering firm evi-
dence of safety. Together, the characterization of the pa-
tient population and development of a scheme to
capture potential adverse events are the first key steps in
determining the type of preclinical data required prior to
submission.
Risks associated with drug manufacturing
Stem cells used in the clinic are drugs and therefore
must be manufactured as drugs. The manufacture of
cell-based medicinal products must be carefully designed
and validated to ensure product consistency and trace-
ability. Control and management of manufacturing and
quality-control testing are carried out according to Good
Manufacturing Practice (GMP) requirements [2]. GMP
include document control, standard operating procedures
(SOPs), trained personnel, qualified reagents and equip-
ment, and complete provenance of the manufacture of the
drug. Prior to their use, drugs must be screened for purity
and potency. Purity in stem cells is usually based on
phenotype characterization by flow cytometry. Potency
testing is used to confirm that the cell-based drug is
biologically active and capable of producing the desired
biological effect [3]. Potency is usually based on the associ-
ation of the phenotype characterization with in vitro activ-
ity such as immune suppression and cell differentiation
[3]. Data demonstrating consistent manufacturing in the
patient population are required. The drugs must also be
assessed to ensure that no additional risks to the patients
(via bacterial contamination or malignant transformation
of the product) were introduced during manufacturing.
Together, these elements (purity, potency, lack of add-
itional risk factors, etc.) make up the release criteria neces-
sary for any stem cell medicinals to be administered to
patients. Ideally, all data supporting the application to the
regulatory agency will be generated identically to the prod-
uct intended to be administered to humans (i.e., cells man-
ufactured using the same SOPs, materials, and cell sources
and meeting identical release criteria) [4]. Although this
may not be possible for all demonstrations of preclinical ef-
ficacy, it should certainly be applied to toxicology studies.
This raises the issues of whether toxicology studies should
be undertaken using human cells in immunocompromised
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animal cells. If cell products are generated in an identical
fashion to the clinical product to be used, the former ap-
proach will be necessary. Additionally, if minor changes to
the process occur after efficacy or toxicology studies are
complete and these do not affect the product, an exception
may be sought. Finally, unique attributes associated with
using cells, such as release criteria, storage requirements,
shipping, and shelf life, require special focused attention to
assure the investigator and regulatory agencies that patients
in a clinical trial will be treated with the same drug.
Small-molecule drugs versus cell therapeutic
Although in some aspects they are quite similar, first-in-
human (FIH) trials using stem cells differ substantially
from the typical FIH trials for small-molecule drugs [5].
Unlike stem cells, small-molecule drugs are composed
of one active ingredient that works on a single target of
action. Drugs often have a stable pharmacokinetic/
pharmacodynamic profile in vivo, and results are easier
to interpret because of the presence of well-defined ref-
erence standards. In contrast to single-modality drugs,
stem cell products are complex and can contain mul-
tiple active ingredients that work through multiple par-
allel mechanistic pathways [3]. Furthermore, stem cells
are living organisms that can produce responses in a
complex multimodal manner depending on the envir-
onmental conditions encountered [3]. For example, this
is the case with adherent stem cell populations in
which it is understood that they exert therapeutic
mechanisms via trophic mechanisms. It is understood
that these trophic pathways are highly responsive to the
microenvironment and are dynamic over time. There-
fore, it is not the same dominant mechanistic pathway
in which the cells will work every time. It is this inher-
ent property of the cell therapy which makes it very dif-
ficult to define reference standards [6] and suitable
assays of potency within the field [3].
Many other differences also exist between the two types
of products. For example, in contrast to small-molecule
drugs, stem cells are a living product and therefore are ad-
ministered without terminal sterilization. Furthermore, dif-
ferences in the absorption, distribution, metabolism, and
excretion profile of the stem cell product after administra-
tion remain unclear. Breakdown/decay of drug concentra-
tions can be monitored in the case of small-molecule drugs
as opposed to stem cell products, where unchecked cell
proliferation may occur and go unmonitored. As a re-
sult, measurements of cell dose may be far less accurate
than those for small-molecule drugs. Furthermore, the
anatomical site of administration proposed for the de-
livery of the stem cells may require surgical interven-
tion or the use of novel cell delivery devices to ensure
adequate delivery of cells. Such procedures pose furthersafety risks. If novel cell delivery devices are required,
safety tests must be carried out to ensure that the ma-
terial of the device in contact with the patient does not
elicit a harmful biological reaction. Furthermore, the
investigator must ensure that the device is sufficient
at delivering the stem cell product without damaging
the delivery system or the product itself. As stem cells
exhibit sensitivities to both chemical and physical
stimuli, the investigator must also ensure that correct
cell identity is maintained after the product is passed
through the device. Another safety concern is the
vulnerability of the administration site (brain/spinal
cord). Each implantation site will have different de-
grees of toxicity associated with cell delivery. In some
cases, it may be necessary to re-access the implant-
ation site in order for product removal in the event of
potential adverse reactions. This will depend on the
individual product specifics and disease indication to
be treated.
What constitutes acceptable data to support
clinical studies?
The reviewed literature can be used as a resource in col-
lecting data to support clinical trials. Articles that de-
scribe other clinical trials with specific details on the
safety of the drug can and should be used to support ar-
guments justifying its safe use in humans. It is important
to be aware that other trials will likely differ in the dose,
route of administration, disease indication, or important
characteristics of the drug used. When identifying data
in publications used to support the argument for their
use in humans, it is important to critically evaluate the
differences in the composition, purity, and potency of
the drug used. In cell therapy, this can be difficult as the
descriptions of the manufacture and evaluation of the
drugs can be rather superficial. Data supporting a related
but unequal drug will likely be considered irrelevant.
However, in situations such as the use of mesenchymal
stromal cells, characterization of the cells as per the
International Society for Cellular Therapy criteria [7]
should allow the use of supporting data from the litera-
ture. Another important issue to consider is the type of
animal model used to support a regulatory submission.
Animal efficacy studies and animal toxicology studies are
significantly different in the number included in the study,
the doses tested, and biological readouts (histology and
non-target organ involvement). Efficacy studies rarely sup-
port the safe use of the drug but are used only for the jus-
tification for the logical testing of the drug in humans.
Animal models of efficacy are justified if the preclinical ef-
ficacy studies were meant to represent highly predictive
models of efficacy in humans or to provide a rationale for
why it is reasonable to progress to human studies. An
ideal scenario would be one in which preclinical data are
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portant to note that, in the US, animal studies of efficacy
are required for testing novel drugs in pediatric patients.
It is important that academic clinicians who are en-
gaged in the translation of stem cell research to the
clinic be cognizant of the requirements of the transla-
tional process from the beginning of the research pro-
gram. The science required to allow the clinical use of a
novel drug is expected to be held to the most rigorous
of standards. A typical mistake of new investigators is to
assume that scientific data published in peer-reviewed
journals automatically qualify as data supporting a clin-
ical trial; often these data do not. Pre-written protocols
for every step of the study, data provenance, equipment
validation, reagents, animals, and supply provenance (re-
cording all lot and catalogue numbers and expiration
dates and methods to ensure that they have been
handled or stored properly prior to use), biometric
monitoring of animals prior to treatment, animal study
randomization, written description of any deviation from
the pre-written protocols, and an independent assess-
ment of the data collected should be taken into consid-
eration to produce data in support of the use of any new
drug in humans. These requirements are typical of the
Good Laboratory Practice (GLP) used in the pharma-
ceutical industry [8]. GLP is important for laboratories
performing preclinical toxicology studies as it ensures
that a system is put in place of documentation and SOPs
to allow the entire study reconstruction once the final
report has been written. Although it is not an absolute
requirement for data in support of a clinical trial, every
effort should be made to adhere to or approximate GLP
principles. Strong self-evaluation of the lab and its prac-
tices (and the appropriate changes needed) is absolutely
required to save the investigator time and money during
the acquisition of the required preclinical data and to
prevent potential repeat of the experiments because of
failed rigor.Toxicology studies
Safety considerations for all drugs should include acute
and long-term toxicology (including effects on non-
target organs) at drug concentrations beyond those
expected to be used in the protocol, specific to the
route of injection [4, 9]. Ideally these studies will be in
an animal model of the disease but this is not always
possible. The optimal safety data are those using pub-
lished human trial data with a drug that is a bio-
equivalent or that has dose and route of delivery
similar to those of the drug. The publication should
specifically report safety outcomes. If using such data,
be aware that significant scrutiny will be placed on
these results.Unique considerations of preclinical studies
relating to cell products
Cell products are guided essentially by the same regula-
tions applied to standard pharmaceuticals. However,
cells used as drugs are often culture-derived. Cells in
culture are populations derived from a complex starting
material that self-purifies during expansion. The culture
process must be robust enough to result in a product
with consistent purity and stability. The basis for evaluat-
ing the rigor of the safety studies in animals stems directly
from the data associated with the reproducibility of the
purity, stability, and potency of the cells generated by the
protocol. Thus, safety data in support of clinical studies
should be produced with a cell culture protocol that meets
GMP processing with sufficient supportive data to ensure
consistency of the production of the drug (cells).
If the actual product cannot be used for preclinical
studies, every effort should be made to ensure that the
preclinical studies are done with equivalent cells. If pub-
lished data are used in support of clinical trials, one
must prove drug equivalency. Proving equivalency is dif-
ficult and complicated by often inadequate description
of manufacturing in published reports. Without equiva-
lency, the drugs cannot be assumed to be functionally or
toxicologically similar.
In early studies, animal models are often used to
evaluate specific safety concerns regarding the drug or
route of injection. Animal safety studies should not be
confused with efficacy studies. Safety studies must be
specifically designed to sufficiently address the question
of safety. One complication of toxicology of stem cell
products is whether a human-based cell therapy or
animal-based one should be used in these studies. If one
needs to use the final product, the former approach will
be necessary. This may necessitate the use of immuno-
compromised animals or a xenogeneic approach. There
is no absolute guidance on which approach is optimal
and this will need to be considered by the investigator
and discussed with the regulator.
One of the challenges in the choice of preclinical ani-
mal models is the limited nature of the relevance of
many of these models to the human situation. Some
models may share similar features in anatomical terms
(e.g., pig heart), but rarely are the pathology and patho-
genesis identical. For example, in translational research
of critical limb ischemia, small animal models of acute
hindlimb ischemia are relatively poor surrogates for
older humans with a history of hypertension, hyperlipid-
emia, diabetes mellitus, and cigarette smoking for many
decades. In addition, dose equivalency is problematic in
animals. For pharmaceutical drugs, the dose size is
merely adjusted on the basis of animal weight. There is
little evidence that the therapeutic value of cells as drugs
relates to a correlative increase in dose. Most likely, cells
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benefit from additional cells. Ultimately, cell dosage will
require empirical evaluation in humans and the trials
should reflect this. Finally, the route of injection has im-
plications for the safety of the approach. It is logical that
intramuscular injection of 300 million cells has a differ-
ent safety profile than those cells injected into the ca-
rotid artery. Delivery into tissues by using needles,
catheters, or adherence to matrices needs to be carefully
evaluated (and maybe evaluated for safety) prior to trial
initiation.
Finally, it is critical for investigators to realize that in
cases of a clinical trial halted because of the safety of the
underlying drug, it is likely that all data in support of the
clinical trial will be audited. The rigor required by adher-
ence to GLP will provide the assurance that a review of
the data, methods, and conclusions will withstand an ar-
duous audit.Phase 1 clinical trial considerations
The primary objective of a phase 1 trial is safety assess-
ment, providing information regarding dosage safety and
the presence or absence of adverse reactions. Phase 1 or
FIH trials can also provide valuable secondary data such
as information on issues of feasibility of administration
and also on the drug’s biological activity. Such data can
be used to design subsequent trials. The following infor-
mation has been adapted from the US Food and Drug
Administration guidelines [10] and will highlight the
points that must be taken into consideration by investi-
gators when designing early FIH clinical trials of cellular
therapy products.Dose exploration
FIH studies can be designed to explore and assess varying
dose ranges. Maximum tolerated doses can be explored
where the product is being used for life-threatening dis-
eases in which some toxicities are anticipated and can be
adequately justified. However, for cases in which minimal
toxicity is expected, the dose to be explored is one that
can be used to decipher ranges in which the product will
produce its maximum biological and therapeutic potential.
In stem cell therapy trials, an additional factor for consid-
eration is the limit on dose production with a focus on es-
tablishing a safety profile for the dose that is most feasible
to produce.Feasibility and delivery
Cell therapy products can require state-of-the-art de-
vices and novel procedures in order to maximize cell de-
livery. FIH trials can be used to discover any technical
issues associated with such procedures.Efficacy assessment
Although safety is the primary objective, preliminary
data on the product’s efficacy can be assessed. Although
most FIH trials will not include a sample size great
enough to truly assess the product’s activity, suggestions
of efficacy as a result of the treatment will provide en-
couragement to strengthen the scientific rationale to
proceed to a phase 2 trial. Caution must be exercised,
however, as phase 1 trials will not include controls.
Choosing a study population
FIH trials are associated with potential risk of unantici-
pated side effects for the patients. Therefore, the correct
patient choice for such trials is very important. Choosing
a patient population can be difficult. However, the trial’s
objective is to select a patient population in which there
is a reasonable balance between potential risks and ben-
efits whilst also accomplishing the scientific objectives of
the study.
As with all clinical trials, patient safety is always a
major concern and this is specifically true for FIH trials.
The possibility of persistent or permanent side effects
coupled with invasive procedures for product delivery
deems such trials unfavorable for healthy volunteers.
The risk-benefit ratio is not optimal for healthy volun-
teers and therefore the use of healthy volunteers is not
acceptable for FIH cell therapy trials.
Patients with severe disease states may be more suit-
able for FIH investigational cell therapy trials as the risk-
benefit ratio may be more acceptable. Despite this, the
selection of the correct study population that will pro-
vide interpretable data involves several considerations.
Patients with a more advanced stage of the disease may
tend to experience adverse events not due to the therapy
but as a result of the disease progression. Adverse events
as such can lead to difficulty in interpreting efficacy and
safety data. However, it may be unacceptable to recruit
patients with a less severe disease state. If no-option pa-
tients are to be included, it is important to ensure that
all of their treatment options have been fully explored
and evaluated and that such information is recorded
carefully. The optimal patient selection criteria for FIH
trials would be those with predictable prognosis, no vi-
able therapeutic alternatives, and sufficient time before
significant morbidity or mortality occurs.
Dose selection
Preclinical strategies can be used to generate sufficient in-
formation on whether a specific starting dose has an ac-
ceptable risk level. However, dose extrapolation using the
allometric scaling method may be less precise than for
those of small-molecule drugs. Furthermore, pharmaco-
kinetics and pharmacodynamics for cell-based drugs may
not be as straightforward to assess and may be difficult to
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mended that, if available, previous clinical data produced
using cell-based drugs, even if by a different route of ad-
ministration, be used to help justify a starting dose for the
trial.
Dose frequency
In most early-phase trials, the administration of the
treatment is a single, one-off, dose. Cell drugs differ
from small-molecules drugs in where they are adminis-
tered, metabolized in the liver, and then cleared from
the body. However, this is not the case for cell-based
drugs, as often such products, once administered, have
the ability to persist within the body and may have a
duration of activity longer than expected. As a conse-
quence, repeated dosing may not be optimal until per-
tinent information regarding the toxicity and duration of
activity of the cells has been obtained.
Dose escalation
Staggering of drug administration is recommended if no
previous human experience has been obtained with the
specific dose in question. In the interest of patient safety,
staggering of the treatment minimizes the number of pa-
tients who are at risk of the unknown side effects of the
drugs. Staggering of the treatment is most often between
cohorts. For dose escalation studies, treatment groups
can be completed sequentially beginning with the lowest
dose. Data should be reviewed by the data monitoring
and safety board prior to escalation. The choice of stag-
gering interval between subjects should be chosen in
such a way that both acute and subacute adverse events
can be monitored. Information on the time course in
which acute and subacute adverse events may occur can
be obtained from preclinical animal data and previous
experience in humans if possible. Furthermore, the dur-
ation of the product’s biological activity should be con-
sidered when choosing the length of the staggering
interval.
Patient-specific products
Cell therapy products are classified as either autologous
or allogeneic. Autologous products involve harvest of
cells and re-administration to the same individual. In
contrast, allogeneic products are obtained from a se-
lected donor who ordinarily will be healthy and multiple
doses may be manufactured for receipt by a number of
individuals.
Since cell therapies can take a considerable amount
of time to manufacture after collection, the patient’s
condition must be taken into consideration. Take for
example the patient who has satisfied the enrollment
criteria at the point of cell collection; however, in the
time it has taken to manufacture the drug, thepatient’s disease status has worsened such that he or
she is no longer eligible to have any further participa-
tion within the trial. To account for such circum-
stances, it is recommended that the trial’s enrollment
criteria contain a set of standards to ensure selection
of patients who will still be eligible for participation
after the manufacturing process is complete. An alter-
native option is that the patients, at the time of ad-
ministration, be required to satisfy an independent set
of criteria before they can be deemed fit to receive
the product.
Another issue that can be encountered upon product
manufacture is failure to successfully generate a product
that can be used for administration for the recipient. It
is important to consider that the patient’s characteristics
can influence such issues. For example, the disease and
age of the patients may be predictors of a poor cell yield
or cell expansion upon ex vivo culture. It can be argued
that likelihood of manufacturing success or failure
should be addressed in the batch runs included in the
investigational medicinal product dossier in the investi-
gational new drug application prior to the trial approval.
However, such studies offer high risk with low benefits
and little or no incentive for the donors to provide such
data. It is optimal to address these manufacturing ques-
tions as part of the phase 1 trial and the data gathered
from this can be used to design later-phase trials. Fur-
thermore, these data will highlight to the investigator a
set of subject selection criteria that are needed to
minimize manufacturing failure.
Safety monitoring and follow-up to mitigate risk to the
patients
Safety monitoring in the FIH trial will depend on the an-
ticipated adverse events associated with the specific
product. Preclinical toxicology studies should provide
sufficient data to help in the choice of safety and moni-
toring tests that must be carried out to assess both an-
ticipated and unanticipated safety concerns. Common
safety tests include general examination and recording
of symptoms, blood chemistry, blood hematology, or
echocardiography if cardiotoxicity is a concern. Immun-
ology tests may also be required if the product is allo-
geneic or poses an autoimmunity risk. However, aside
from the general safety tests, specific tests and monitor-
ing related to product-specific anticipated events should
be considered. Such tests should be carefully chosen
once the capabilities of the monitoring tools and analytic
methods available at the trial site have been reviewed. In
light of this, specific safety and monitoring procedures
relevant to the stem cell product should be implemented
prior to the trial initiation. For example, immunological
assays such as cell and humoral responses should be
evaluated if immunogenicity of the product is a safety
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been developed, retention of the baseline and treatment
plasma or serum should be considered. This will enable
sample evaluation when such assays are made available.
It is also suggested that attempts to evaluate product
persistence or biological activity be carried out. Such as-
sessments can be made at the region of administration
or from the site of the product’s proposed therapeutic
activity. This may be possible only if a biopsy can be eas-
ily obtained. In addition, protocols can be put in place to
require the appropriate post-mortem studies on tissues/
organs to assess the persistence or migration of the
product should a patient die during the trial [11]. Fur-
thermore, if applicable to the trial site, imaging studies
can be used to monitor any ectopic formation or aber-
rant cell activity.
Stem cell therapies are still in the experimental phase
and therefore uncertainties regarding the frequency or
severity of adverse events remain. The inclusion of
trial-stopping rules into the protocol can enable the in-
vestigator to control the number of patients who are
put at risk, particularly if safety concerns arise early in
the trial. Stopping rules define the number of events or
unexpected deaths necessary to put a temporary halt to
trial enrollment or dosing. The inclusion of stopping
rules does not imply that if such events occur the trial
will be terminated but it allows the trial to be tempor-
arily suspended until an adequate assessment of the
situation has occurred. This can be beneficial to the
trial as the correct assessment can enable the revision
of the clinical trial protocol in a manner which benefits
the safety and welfare of the patient. For example, revi-
sions of the trial protocol may be made after the assess-
ment to exclude individuals who are more susceptible
or at high risk of developing adverse events.
To further reduce the risk for patients enrolled in the
trial, suitable follow-up protocols are suggested to be in-
corporated into the trial design. Preclinical studies, fa-
miliarity with the disease, and expertise with the stem
cell product will help investigators choose a suitable
follow-up time. In the event that the patient fails to re-
ceive the product (that is, disease severity worsens and
now the patient fails to meet the inclusion criteria), a
suitable follow-up protocol must be in place that allows
the risk assessment of the cell-harvesting procedure or
any subsequent preparation that the patient may have
received before the trial. Long-term patient monitoring
is integral to the trial design. Long-term follow-up visits
are not required to be as detailed as the initial safety as-
sessments provided in the trial. In some instances, brief
phone calls to the patient may be sufficient to obtain the
required information. Long-term monitoring usually will
focus on post-trial patient survival and frequency of ad-
verse events.Final statement of working with regulatory
agencies
As with all new therapeutic strategies, our information
regarding the biological effect of stromal cells is limited
and therefore methods to assess safety and efficacy need
to be constantly expanded. Adherent stem cell popula-
tions such as human mesenchymal stem cells are often
portrayed as stem cells that are a well-understood,
homogenous population of cells that exhibit predictable
properties. Although they are the most extensively stud-
ied and characterized cell type, great diversity exists in
how investigators have defined and manufactured these
cells. Major differences in terms of cell sourcing, product
manufacture, and cell surface marker expression exist
amongst different laboratories [5]. In addition, differ-
ences in the in vitro and in vivo bioactivity of the cells
have been reported and these can vary depending on the
donor source. With immense speculation surrounding
the field and pressure to deliver effective therapies to pa-
tients, product quality and consistency are of utmost im-
portance. Identification of parameters important to the
cell safety and efficacy is important to ensure quality.
Development of assays and screening for stem cell spe-
cific markers early in product development will help
build our knowledge about the in vitro and in vivo bio-
activity of the cell product. The discovery of biological
markers that can predict the intended biologic effect which
then can be correlated with a beneficial clinical response is
essential. Once identified, these parameters can be con-
trolled for in a manner in which the product can be manu-
factured with a high degree of quality and consistency.
The investment in the development and refinement of
new and existing technologies is ongoing in the stem cell
field. The development of more advanced preclinical
models such as humanized mice and replacement of the
use of animal-derived sera in the culture media with
safer alternatives such as human platelet lysate is facili-
tating the development of safer stem cell products.
Regulatory agencies around the world are interested in
promoting the safe and effective investigation of novel
therapies. Investigators should not consider that they are
working alone or in an antagonistic manner on their novel
therapies. We strongly recommend that, when planning to
apply for FIH stem cell trials, the investigator become fa-
miliar with the country-specific process, read and follow
all guidance documents, and engage with the agencies
early in the development of their process. In addition, the
discipline required with FIH trials is worthy of pursuit and
involves a close interaction between academic investiga-
tors, industry, and regulators. Progress in the therapeutic
use of cell-based therapies requires investigators to have
the skills to navigate the regulatory environment, develop
appropriately designed clinic trials, and consistently
manufacture this new class of exciting therapies.
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